Second, delivery optimization via antibody-drug conjugates (ADCs) [122] could exploit tumor-specific antigens (e.g. HER2 [123], TROP-2 [124]) to localize inhibitors (e.g. FTO or ALKBH5 inhibitors) to cancer cells, leveraging stable linkers and high drug-antibody ratios (DAR) to minimize off-target immune suppression. Here, ALKBH5 is linked to neoplasm.